Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BristolMyers Squibb

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 10 strange trades.

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What Are Whales Doing With Bristol-Myers Squibb

Benzinga

Looking At Bristol-Myers Squibb's Recent Whale Trades

Benzinga

Bristol-Myers Squibb Whale Trades For July 12

Benzinga

Bristol-Myers Squibb Whale Trades For July 07

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Is What Whales Are Betting On Bristol-Myers Squibb

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 12 strange trades.

Benzinga

Looking Into Bristol-Myers Squibb's Recent Short Interest

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 4.49% since its last report. The company recently reported that it has 34.46 million shares sold short, which is 1.63% of all regular shares that are available for trading.

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Cisco And 2 Other Stocks Insiders Are Selling

US stock futures traded higher this morning on Wednesday ahead of the key interest rate decision from the Federal Reserve. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 11 strange trades.

Benzinga

Peering Into Bristol-Myers Squibb's Recent Short Interest

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.98% since its last report. The company recently reported that it has 32.18 million shares sold short, which is 1.52% of all regular shares that are available for trading.

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 25 strange trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Upgrades

Benzinga

What 7 Analyst Ratings Have To Say About Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

Benzinga

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and…

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Analyzing Bristol-Myers Squibb's Short Interest

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, which is 1.99% of all regular shares that are available for trading.

Tribune News Service

Warren Buffett’s portfolio: Here are the stocks Berkshire Hathaway is buying or selling

Warren Buffett is arguably the world’s most famous investor, and his investment moves are closely followed. Each quarter, the company he runs, Berkshire Hathaway, discloses its current holdings to shareholders.

Benzinga

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.

Benzinga

Peering Into Bristol-Myers Squibb's Recent Short Interest

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.23% since its last report. The company recently reported that it has 47.34 million shares sold short, which is 2.23% of all regular shares that are available for trading.

Benzinga

Check Out What Whales Are Doing With BMY

Benzinga

Bristol-Myers Squibb's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Bristol-Myers Squibb (NYSE:BMY) earned $1.28 billion, a 45.91% increase from the preceding quarter. Bristol-Myers Squibb's sales decreased to $11.65 billion, a 2.81% change since Q4.

Benzinga

What 4 Analyst Ratings Have To Say About Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

1 2 3

People

Warren Buffett

2,027 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

340 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.